Combination of crafity score with alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Wei Teng, Chen‐Chun Lin, Po Ting Lin, Yi‐Chung Hsieh, M. Ho, Chia-Hsun Hsieh, Chun‐Yen Lin, Shi‐Ming Lin
Topics & Concepts
AtezolizumabMedicineBevacizumabInternal medicineHepatocellular carcinomaHazard ratioGastroenterologyOdds ratioResponse Evaluation Criteria in Solid TumorsOncologyConfidence intervalProgressive diseaseCancerNivolumabImmunotherapyChemotherapyHepatocellular Carcinoma Treatment and PrognosisPancreatic and Hepatic Oncology ResearchRenal cell carcinoma treatment